Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NDRG1 plasmid is an experimental genetic construct used in molecular biology and oncology research to overexpress the N-myc downstream-regulated gene-1 (NDRG1) protein. NDRG1 is a member of the NDRG family and is known to play a complex, often tissue-specific role in cancer, frequently acting as a metastasis suppressor by inhibiting pathways such as Wnt/β-catenin, TGF-β, and PI3K/AKT. In research settings, transfection with an NDRG1 plasmid allows scientists to study the effects of high NDRG1 levels on cell proliferation, migration, and invasion. For instance, in head and neck cancer (HNC) models, it has been shown to suppress growth while potentially increasing invasion in certain contexts. While NDRG1 itself is a target for therapeutic induction (e.g., by thiosemicarbazones), the plasmid form is primarily a laboratory tool rather than a clinical drug candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NDRG1 plasmid.